vs
盖尔斯（GES）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
盖尔斯的季度营收约是Royalty Pharma plc的1.3倍（$791.4M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 3.2%，领先31.2%），盖尔斯同比增速更快（7.2% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -5.8%）
盖尔斯是美国知名服饰品牌企业，以标志性的黑白风格广告广为人知。除核心服饰产品外，品牌还通过品牌授权模式推出腕表、珠宝、香水、包袋、鞋履等各类时尚配饰，在全球时尚消费市场拥有较高知名度。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
GES vs RPRX — 直观对比
营收规模更大
GES
是对方的1.3倍
$622.0M
营收增速更快
GES
高出2.4%
4.8%
净利率更高
RPRX
高出31.2%
3.2%
两年增速更快
RPRX
近两年复合增速
-5.8%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $791.4M | $622.0M |
| 净利润 | $25.6M | $214.2M |
| 毛利率 | 42.5% | — |
| 营业利润率 | 2.9% | 62.4% |
| 净利率 | 3.2% | 34.4% |
| 营收同比 | 7.2% | 4.8% |
| 净利润同比 | 209.6% | 2.9% |
| 每股收益（稀释后） | $0.48 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GESRPRX
| Q4 25 | $791.4M | $622.0M | ||
| Q3 25 | $772.9M | $609.3M | ||
| Q2 25 | $647.8M | $578.7M | ||
| Q1 25 | $932.3M | $568.2M | ||
| Q4 24 | $738.5M | $593.6M | ||
| Q3 24 | $732.6M | $564.7M | ||
| Q2 24 | $591.9M | $537.3M | ||
| Q1 24 | $891.0M | $568.0M |
净利润GESRPRX
| Q4 25 | $25.6M | $214.2M | ||
| Q3 25 | $6.2M | $288.2M | ||
| Q2 25 | $-32.9M | $30.2M | ||
| Q1 25 | $81.4M | $238.3M | ||
| Q4 24 | $-23.4M | $208.2M | ||
| Q3 24 | $-10.6M | $544.0M | ||
| Q2 24 | $13.0M | $102.0M | ||
| Q1 24 | $115.3M | $4.8M |
毛利率GESRPRX
| Q4 25 | 42.5% | — | ||
| Q3 25 | 42.5% | — | ||
| Q2 25 | 39.9% | — | ||
| Q1 25 | 44.1% | — | ||
| Q4 24 | 43.6% | — | ||
| Q3 24 | 43.7% | — | ||
| Q2 24 | 41.9% | — | ||
| Q1 24 | 45.4% | — |
营业利润率GESRPRX
| Q4 25 | 2.9% | 62.4% | ||
| Q3 25 | 2.3% | 70.1% | ||
| Q2 25 | -5.1% | 36.3% | ||
| Q1 25 | 11.1% | 94.0% | ||
| Q4 24 | 5.7% | 60.9% | ||
| Q3 24 | 6.5% | — | ||
| Q2 24 | -3.4% | 50.2% | ||
| Q1 24 | 16.3% | -13.0% |
净利率GESRPRX
| Q4 25 | 3.2% | 34.4% | ||
| Q3 25 | 0.8% | 47.3% | ||
| Q2 25 | -5.1% | 5.2% | ||
| Q1 25 | 8.7% | 41.9% | ||
| Q4 24 | -3.2% | 35.1% | ||
| Q3 24 | -1.4% | 96.3% | ||
| Q2 24 | 2.2% | 19.0% | ||
| Q1 24 | 12.9% | 0.8% |
每股收益（稀释后）GESRPRX
| Q4 25 | $0.48 | $0.49 | ||
| Q3 25 | $0.12 | $0.67 | ||
| Q2 25 | $-0.65 | $0.07 | ||
| Q1 25 | $1.29 | $0.55 | ||
| Q4 24 | $-0.47 | $0.46 | ||
| Q3 24 | $-0.28 | $1.21 | ||
| Q2 24 | $0.23 | $0.23 | ||
| Q1 24 | $1.90 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $154.2M | $618.7M |
| 总债务越低越好 | $299.5M | $9.0B |
| 股东权益账面价值 | $508.5M | $9.7B |
| 总资产 | $3.0B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.59× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资GESRPRX
| Q4 25 | $154.2M | $618.7M | ||
| Q3 25 | $189.6M | $938.9M | ||
| Q2 25 | $151.2M | $631.9M | ||
| Q1 25 | $187.7M | $1.1B | ||
| Q4 24 | $140.9M | $929.0M | ||
| Q3 24 | $218.9M | $950.1M | ||
| Q2 24 | $241.7M | $1.8B | ||
| Q1 24 | $360.3M | $843.0M |
总债务GESRPRX
| Q4 25 | $299.5M | $9.0B | ||
| Q3 25 | $258.4M | $8.9B | ||
| Q2 25 | $241.7M | $8.0B | ||
| Q1 25 | $150.7M | $7.6B | ||
| Q4 24 | $238.3M | $7.6B | ||
| Q3 24 | $187.8M | $7.6B | ||
| Q2 24 | $196.9M | $7.6B | ||
| Q1 24 | $28.2M | $6.1B |
股东权益GESRPRX
| Q4 25 | $508.5M | $9.7B | ||
| Q3 25 | $487.6M | $9.6B | ||
| Q2 25 | $483.6M | $9.5B | ||
| Q1 25 | $505.0M | $9.8B | ||
| Q4 24 | $450.7M | $10.3B | ||
| Q3 24 | $491.2M | $10.3B | ||
| Q2 24 | $565.5M | $9.8B | ||
| Q1 24 | $684.9M | $9.9B |
总资产GESRPRX
| Q4 25 | $3.0B | $19.6B | ||
| Q3 25 | $3.0B | $19.3B | ||
| Q2 25 | $2.9B | $18.3B | ||
| Q1 25 | $2.8B | $17.6B | ||
| Q4 24 | $2.8B | $18.2B | ||
| Q3 24 | $2.8B | $18.0B | ||
| Q2 24 | $2.7B | $17.7B | ||
| Q1 24 | $2.6B | $16.1B |
负债/权益比GESRPRX
| Q4 25 | 0.59× | 0.92× | ||
| Q3 25 | 0.53× | 0.93× | ||
| Q2 25 | 0.50× | 0.84× | ||
| Q1 25 | 0.30× | 0.78× | ||
| Q4 24 | 0.53× | 0.74× | ||
| Q3 24 | 0.38× | 0.74× | ||
| Q2 24 | 0.35× | 0.78× | ||
| Q1 24 | 0.04× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-39.5M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-56.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | -1.54× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $62.5M | — |
8季度趋势，按日历期对齐
经营现金流GESRPRX
| Q4 25 | $-39.5M | $827.1M | ||
| Q3 25 | $74.9M | $702.6M | ||
| Q2 25 | $-73.4M | $364.0M | ||
| Q1 25 | $183.2M | $596.1M | ||
| Q4 24 | $-83.3M | $742.5M | ||
| Q3 24 | $44.7M | $703.6M | ||
| Q2 24 | $-22.9M | $658.2M | ||
| Q1 24 | $289.5M | $664.6M |
自由现金流GESRPRX
| Q4 25 | $-56.3M | — | ||
| Q3 25 | $53.4M | — | ||
| Q2 25 | $-95.3M | — | ||
| Q1 25 | $160.7M | — | ||
| Q4 24 | $-105.4M | — | ||
| Q3 24 | $24.3M | — | ||
| Q2 24 | $-44.0M | — | ||
| Q1 24 | $267.8M | — |
自由现金流率GESRPRX
| Q4 25 | -7.1% | — | ||
| Q3 25 | 6.9% | — | ||
| Q2 25 | -14.7% | — | ||
| Q1 25 | 17.2% | — | ||
| Q4 24 | -14.3% | — | ||
| Q3 24 | 3.3% | — | ||
| Q2 24 | -7.4% | — | ||
| Q1 24 | 30.1% | — |
资本支出强度GESRPRX
| Q4 25 | 2.1% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 3.4% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 3.6% | — | ||
| Q1 24 | 2.4% | — |
现金转化率GESRPRX
| Q4 25 | -1.54× | 3.86× | ||
| Q3 25 | 12.00× | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | 2.25× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | -1.76× | 6.45× | ||
| Q1 24 | 2.51× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GES
| Products | $760.3M | 96% |
| Royalty | $31.1M | 4% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
